股本结构
单位：万股
| 公告日期 | 2025-11-12 | 2025-11-12 | 2025-09-11 | 2025-08-12 | 2025-08-12 | 2025-05-30 |
|---|---|---|---|---|---|---|
| 证券总股本 | 13768.30 | 13092.47 | 13722.75 | 10847.75 | 10841.10 | 10819.46 |
| 普通股本 | 13768.30 | 13092.47 | 13722.75 | 10847.75 | 10841.10 | 10819.46 |
| 优先股 | 未披露 | 5.43 | 未披露 | 未披露 | 5.44 | 未披露 |
| 其他 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 变动日期 | 2025-11-07 | 2025-09-30 | 2025-09-11 | 2025-08-08 | 2025-06-30 | 2025-05-27 |
注释：中概股证券总股本=普通股股本/
存托凭证比例
历史变动
| 公告日期 | 变动后普通股本（万股） | 变动后优先股（万股） | 变动原因 | 变动日期 |
|---|---|---|---|---|
| 2025-12-05 | 13768.30 | 5.43 | 定期报告 | 2025-12-01 |
| 2025-11-12 | 13768.30 | 未披露 | 定期报告 | 2025-11-07 |
| 2025-11-12 | 13092.47 | 5.43 |
更多>>
From June 30, 2025 to September 30, 2025
Conversions - Series B Preferred Stock
Purchase - Employee Stock Purchase Plan
Issuance - Interest payment paid in stock
Issue common stock - vendor service agreement
Issuance - Confidentially Marketed Public Offering, net of fees
|
2025-09-30 |
| 2025-09-11 | 13722.75 | 未披露 |
更多>>
Securities offered 25,000,000 shares of common stock by the company
The underwriters exercised their option to purchase common stock 3,750,000 shares
|
2025-09-11 |
| 2025-08-12 | 10847.75 | 未披露 | 定期报告 | 2025-08-08 |
| 2025-08-12 | 10841.10 | 5.44 |
更多>>
From March 31, 2025 to June 30, 2025
Exercise - stock options - Lucid Diagnostics Inc. 2018 Equity Plan
Issuance - At-The-Market Facility, net of deferred financing charges
Issuance - Interest payment paid in stock
Issuance - Confidentially Marketed Public Offering, net of fees
Issuance - Dividend on Series B and Series B-1 Preferred Stock
|
2025-06-30 |
| 2025-05-30 | 10819.46 | 未披露 | 定期报告 | 2025-05-27 |
| 2025-05-13 | 10818.90 | 未披露 | 定期报告 | 2025-05-09 |
| 2025-04-30 | 10538.30 | 5.44 | 定期报告 | 2025-04-22 |
| 2025-04-11 | 10533.37 | 未披露 |
更多>>
Common stock offered 14,375,000 shares by the company
|
2025-04-11 |
| 2025-05-13 | 8437.45 | 5.44 |
更多>>
From December 31, 2024 to March 31, 2025
Exercise - stock options - Lucid Diagnostics Inc. 2018 Equity Plan
Purchase - Employee Stock Purchase Plan
Issuance - Interest payment paid in stock
Issuance - Registered Direct Offering, net of fees
Issuance - Dividend on Series B Preferred Stock
|
2025-03-31 |
| 2025-03-24 | 9075.39 | 未披露 | 定期报告 | 2025-03-20 |
| 2025-03-05 | 8363.64 | 未披露 |
更多>>
Securities offered 13,939,331 shares of common stock by the company
|
2025-03-05 |
| 2025-03-05 | 6969.71 | 未披露 | 定期报告 | 2025-02-28 |
| 2025-03-24 | 6307.20 | 5.44 |
更多>>
From December 31, 2023 to December 31, 2024
Conversions - Series B Preferred Stock
Vest - restricted stock awards
Issuance through exchange - Series B and Series B-1 Preferred Stock
Exchange - Series A and Series A-1 Preferred Stock
Purchase - Employee Stock Purchase Plan
Issuance through sale- Series B and Series B-1 Preferred Stock
Conversions - Senior Secured Convertible Note
Issuance - Series A-1 Preferred Stock
Exercise - stock options - Lucid Diagnostics Inc. 2018 Equity Plan
Issuance - Due To: PAVmed Inc. Settlement in Common Stock
Issue common stock - vendor service agreement
|
2024-12-31 |
| 2024-11-12 | 5544.50 | 未披露 | 定期报告 | 2024-11-08 |
| 2024-11-12 | 5159.77 | 5.59 |
更多>>
From June 30, 2024 to September 30, 2024
Conversions - Senior Secured Convertible Note
Purchase - Employee Stock Purchase Plan
|
2024-09-30 |
| 2024-08-12 | 5399.03 | 未披露 | 定期报告 | 2024-08-08 |
| 2024-08-12 | 4934.49 | 5.59 |
更多>>
From March 31, 2024 to June 30, 2024
Issuance - Series B-1 Preferred Stock
Conversions - Senior Secured Convertible Note
Issue common stock - vendor service agreement
|
2024-06-30 |
| 2024-06-06 | 5241.80 | 4.43 | 定期报告 | 2024-05-29 |
| 2024-05-24 | 5231.86 | 未披露 | 定期报告 | 2024-05-20 |
| 2024-05-13 | 5211.44 | 未披露 | 定期报告 | 2024-05-09 |
| 2024-04-29 | 4978.45 | 4.43 | 定期报告 | 2024-04-22 |
| 2024-05-13 | 4674.71 | 4.43 |
更多>>
From December 31, 2023 to March 31, 2024
Exercise - stock options - Lucid Diagnostics Inc. 2018 Equity Plan
Vest - restricted stock awards
Conversions - Senior Secured Convertible Note
Purchase - Employee Stock Purchase Plan
Issuance - Due To: PAVmed Inc. Settlement in Common Stock
|
2024-03-31 |
| 2024-03-25 | 4824.48 | 未披露 | 定期报告 | 2024-03-21 |
| 2024-03-25 | 4232.99 | 1.86 |
更多>>
From December 31, 2022 to December 31, 2023
Issuance common stock - APA-RDx - Termination payment
Issue common stock - vendor service agreement
Conversions - Senior Secured Convertible Note
Vest - restricted stock awards
Issuance - At-The-Market Facility, net of financing charges
Purchase - Employee Stock Purchase Plan
|
2023-12-31 |
| 2023-11-13 | 4466.73 | 未披露 | 定期报告 | 2023-11-09 |
| 2023-11-13 | 4232.99 | 1.36 |
更多>>
From June 30, 2023 to September 30, 2023
Conversions - Senior Secured Convertible Note
Purchase - Employee Stock Purchase Plan
Vest - restricted stock awards
|
2023-09-30 |
| 2023-08-14 | 4372.57 | 未披露 | 定期报告 | 2023-08-10 |
| 2023-08-14 | 4185.36 | 1.36 |
更多>>
From March 31, 2023 to June 30, 2023
Issue common stock - vendor service agreement
|
2023-06-30 |
| 2023-05-01 | 4372.57 | 未披露 | 定期报告 | 2023-04-25 |
| 2023-05-15 | 4175.36 | 1.36 |
更多>>
From December 31, 2022 to March 31, 2023
Vest - restricted stock awards
Issuance - At-The-Market Facility, net of deferred financing charges
APA-RDx - Termination payment
Purchase - Employee Stock Purchase Plan
Issuance - Series A Preferred Stock
|
2023-03-31 |
| 2023-03-14 | 4339.37 | 未披露 | 定期报告 | 2023-03-09 |
| 2023-03-14 | 4051.88 | 未披露 |
更多>>
From December 31, 2021 to December 31, 2022
Exercise - stock options - Lucid Diagnostics Inc. 2018 Equity Plan
Vest - restricted stock awards
APA-RDx - Installment Payment
Issuance - Committed Equity Facility, net of financing charges
Purchase - Employee Stock Purchase Plan
Issuance - Due To: PAVmed Inc. Settlement in Common Stock
|
2022-12-31 |
| 2022-11-25 | 3910.76 | 未披露 | 定期报告 | 2022-11-16 |
| 2022-11-14 | 3910.82 | 未披露 | 定期报告 | 2022-11-10 |
| 2022-11-14 | 3701.62 | 未披露 |
更多>>
From June 30, 2022 to September 30, 2022
Exercise - stock options - Lucid Diagnostics Inc. 2018 Equity Plan
Vest - restricted stock awards
APA-RDx - Installment Payment
Issuance - Committed Equity Facility, net of deferred financing charges
Purchase - Employee Stock Purchase Plan
|
2022-09-30 |
| 2022-08-15 | 3856.85 | 未披露 | 定期报告 | 2022-08-10 |
| 2022-08-15 | 3599.47 | 未披露 |
更多>>
From March 31, 2022 to June 30, 2022
APA-RDx - Installment Payment
Exercise - stock options - Lucid Diagnostics Inc. 2018 Equity Plan
|
2022-06-30 |
| 2022-05-16 | 3813.80 | 未披露 | 定期报告 | 2022-05-12 |
| 2022-05-02 | 3793.25 | 未披露 | 定期报告 | 2022-04-25 |
| 2022-05-16 | 3517.18 | 未披露 |
更多>>
From December 31, 2021 to March 31, 2022
Exercise - stock options - Lucid Diagnostics Inc. 2018 Equity Plan
|
2022-03-31 |
| 2022-04-06 | 3743.25 | 未披露 | 定期报告 | 2022-03-29 |
| 2022-04-06 | 3491.79 | 未披露 |
更多>>
From December 31, 2020 to December 31, 2021
Issue of common stock - conversion of Senior Unsecured Promissory Note
Issuance of common stock - IPO, net of fees
|
2021-12-31 |
| 2021-11-23 | 3680.86 | 未披露 | 定期报告 | 2021-11-18 |
| 2021-10-15 | 3699.21 | 未披露 |
更多>>
1.Common stock being offered 5,000,000 shares.
2.Unless expressly indicated or the context requires otherwise, all information in this prospectus, including the number of shares that will be outstanding after this offering, is based on a total of 31,723,987 shares outstanding immediately prior to this offering, inclusive of 1,806,080 shares underlying unvested restricted stock awards and 15,803,200 shares issued to PAVmed upon conversion of the $22.4 million face value principal of the Convertible Note.
|
2021-10-14 |
| 2021-11-23 | 1411.47 | 未披露 | 定期报告 | 2021-09-30 |
From June 30, 2025 to September 30, 2025
Conversions - Series B Preferred Stock
Purchase - Employee Stock Purchase Plan
Issuance - Interest payment paid in stock
Issue common stock - vendor service agreement
Issuance - Confidentially Marketed Public Offering, net of fees
Securities offered 25,000,000 shares of common stock by the company
The underwriters exercised their option to purchase common stock 3,750,000 shares
From March 31, 2025 to June 30, 2025
Exercise - stock options - Lucid Diagnostics Inc. 2018 Equity Plan
Issuance - At-The-Market Facility, net of deferred financing charges
Issuance - Interest payment paid in stock
Issuance - Confidentially Marketed Public Offering, net of fees
Issuance - Dividend on Series B and Series B-1 Preferred Stock
Common stock offered 14,375,000 shares by the company
From December 31, 2024 to March 31, 2025
Exercise - stock options - Lucid Diagnostics Inc. 2018 Equity Plan
Purchase - Employee Stock Purchase Plan
Issuance - Interest payment paid in stock
Issuance - Registered Direct Offering, net of fees
Issuance - Dividend on Series B Preferred Stock
Securities offered 13,939,331 shares of common stock by the company
From December 31, 2023 to December 31, 2024
Conversions - Series B Preferred Stock
Vest - restricted stock awards
Issuance through exchange - Series B and Series B-1 Preferred Stock
Exchange - Series A and Series A-1 Preferred Stock
Purchase - Employee Stock Purchase Plan
Issuance through sale- Series B and Series B-1 Preferred Stock
Conversions - Senior Secured Convertible Note
Issuance - Series A-1 Preferred Stock
Exercise - stock options - Lucid Diagnostics Inc. 2018 Equity Plan
Issuance - Due To: PAVmed Inc. Settlement in Common Stock
Issue common stock - vendor service agreement
From June 30, 2024 to September 30, 2024
Conversions - Senior Secured Convertible Note
Purchase - Employee Stock Purchase Plan
From March 31, 2024 to June 30, 2024
Issuance - Series B-1 Preferred Stock
Conversions - Senior Secured Convertible Note
Issue common stock - vendor service agreement
From December 31, 2023 to March 31, 2024
Exercise - stock options - Lucid Diagnostics Inc. 2018 Equity Plan
Vest - restricted stock awards
Conversions - Senior Secured Convertible Note
Purchase - Employee Stock Purchase Plan
Issuance - Due To: PAVmed Inc. Settlement in Common Stock
From December 31, 2022 to December 31, 2023
Issuance common stock - APA-RDx - Termination payment
Issue common stock - vendor service agreement
Conversions - Senior Secured Convertible Note
Vest - restricted stock awards
Issuance - At-The-Market Facility, net of financing charges
Purchase - Employee Stock Purchase Plan
From June 30, 2023 to September 30, 2023
Conversions - Senior Secured Convertible Note
Purchase - Employee Stock Purchase Plan
Vest - restricted stock awards
From March 31, 2023 to June 30, 2023
Issue common stock - vendor service agreement
From December 31, 2022 to March 31, 2023
Vest - restricted stock awards
Issuance - At-The-Market Facility, net of deferred financing charges
APA-RDx - Termination payment
Purchase - Employee Stock Purchase Plan
Issuance - Series A Preferred Stock
From December 31, 2021 to December 31, 2022
Exercise - stock options - Lucid Diagnostics Inc. 2018 Equity Plan
Vest - restricted stock awards
APA-RDx - Installment Payment
Issuance - Committed Equity Facility, net of financing charges
Purchase - Employee Stock Purchase Plan
Issuance - Due To: PAVmed Inc. Settlement in Common Stock
From June 30, 2022 to September 30, 2022
Exercise - stock options - Lucid Diagnostics Inc. 2018 Equity Plan
Vest - restricted stock awards
APA-RDx - Installment Payment
Issuance - Committed Equity Facility, net of deferred financing charges
Purchase - Employee Stock Purchase Plan
From March 31, 2022 to June 30, 2022
APA-RDx - Installment Payment
Exercise - stock options - Lucid Diagnostics Inc. 2018 Equity Plan
From December 31, 2021 to March 31, 2022
Exercise - stock options - Lucid Diagnostics Inc. 2018 Equity Plan
From December 31, 2020 to December 31, 2021
Issue of common stock - conversion of Senior Unsecured Promissory Note
Issuance of common stock - IPO, net of fees
1.Common stock being offered 5,000,000 shares.
2.Unless expressly indicated or the context requires otherwise, all information in this prospectus, including the number of shares that will be outstanding after this offering, is based on a total of 31,723,987 shares outstanding immediately prior to this offering, inclusive of 1,806,080 shares underlying unvested restricted stock awards and 15,803,200 shares issued to PAVmed upon conversion of the $22.4 million face value principal of the Convertible Note.